VK2809

VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. It is being developed by Viking Therapeutics in a phase II trial for the treatment of nonalcoholic steatohepatitis and is also being investigated for glycogen storage disease type Ia.